Drugs / [177Lu]-NeoB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03872778 | May 2019 → Jan 2025 | neoplasm | Advanced Accelerator Applications | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]-NeoB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03872778 ↗ |
| Action | Inhibit | “NeoB, a high affinity antagonist for GRPR” NCT03872778 ↗ |
| Modality | Peptide | “peptide receptor radionuclide therapy” NCT03872778 ↗ |